ES2627334T3 - Endoglucosidasa de streptococcus pyogenes y métodos para usarla - Google Patents
Endoglucosidasa de streptococcus pyogenes y métodos para usarla Download PDFInfo
- Publication number
- ES2627334T3 ES2627334T3 ES12756523.2T ES12756523T ES2627334T3 ES 2627334 T3 ES2627334 T3 ES 2627334T3 ES 12756523 T ES12756523 T ES 12756523T ES 2627334 T3 ES2627334 T3 ES 2627334T3
- Authority
- ES
- Spain
- Prior art keywords
- endos49
- igg
- polypeptide
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 241000193996 Streptococcus pyogenes Species 0.000 title description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 73
- 229920001184 polypeptide Polymers 0.000 claims abstract description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 72
- 230000000694 effects Effects 0.000 claims abstract description 38
- 150000001413 amino acids Chemical class 0.000 claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 22
- 230000022811 deglycosylation Effects 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 229920001503 Glucan Polymers 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 238000011534 incubation Methods 0.000 claims description 8
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 108090000288 Glycoproteins Proteins 0.000 description 24
- 102000003886 Glycoproteins Human genes 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 230000007935 neutral effect Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000003301 hydrolyzing effect Effects 0.000 description 13
- 230000003197 catalytic effect Effects 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 10
- 102400001364 Alpha-1-microglobulin Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 7
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 7
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229940082789 erbitux Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 101150079601 recA gene Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000672609 Escherichia coli BL21 Species 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940120638 avastin Drugs 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
- 229960003669 carbenicillin Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100001093 Arabidopsis thaliana AAE7 gene Proteins 0.000 description 1
- 101100377798 Arabidopsis thaliana ABCD1 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 101000631695 Homo sapiens Succinate dehydrogenase assembly factor 3, mitochondrial Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101100116805 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SDH4 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 102100028996 Succinate dehydrogenase assembly factor 3, mitochondrial Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000011326 acute poststreptococcal glomerulonephritis Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- -1 aliphatic amino acid Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108700004049 glycosylated serum Proteins 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 108010034897 lentil lectin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003535 nephritogenic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56944—Streptococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201115841A GB201115841D0 (en) | 2011-09-13 | 2011-09-13 | Protein and method |
| GB201115841 | 2011-09-13 | ||
| PCT/EP2012/067841 WO2013037824A1 (en) | 2011-09-13 | 2012-09-12 | Endoglycosidase from streptococcus pyogenes and methods using it |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2627334T3 true ES2627334T3 (es) | 2017-07-27 |
Family
ID=44908522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12756523.2T Active ES2627334T3 (es) | 2011-09-13 | 2012-09-12 | Endoglucosidasa de streptococcus pyogenes y métodos para usarla |
Country Status (20)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002216863B8 (en) * | 2000-12-21 | 2008-03-20 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| RS64329B1 (sr) | 2012-10-23 | 2023-08-31 | Synaffix Bv | Modifikovano antitelo, konjugat antitela i postupak za njihovo pripremanje |
| WO2014177771A1 (en) | 2013-05-02 | 2014-11-06 | Glykos Finland Oy | Conjugates of a glycoprotein or a glycan with a toxic payload |
| EP2935608A1 (en) | 2013-10-14 | 2015-10-28 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| EP3929301A1 (en) | 2013-10-14 | 2021-12-29 | SynAffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| WO2015057064A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| WO2015057065A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| GB201318490D0 (en) * | 2013-10-18 | 2013-12-04 | Genovis Ab | Method |
| EP3097079B1 (en) | 2014-01-24 | 2021-05-12 | SynAffix B.V. | Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne |
| CA2954934C (en) | 2014-06-30 | 2023-09-26 | Glykos Finland Oy | Drug derivative and conjugates |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| EP3177633B1 (en) | 2014-08-04 | 2022-07-20 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| JP6966162B2 (ja) | 2015-04-23 | 2021-11-10 | シンアフィックス ビー．ブイ． | β（１，４）−Ｎ−アセチルガラクトサミニルトランスフェラーゼであるか又はそれに由来するグリコシルトランスフェラーゼを用いる糖タンパク質の改変方法 |
| US11008601B2 (en) | 2016-01-15 | 2021-05-18 | University Of Maryland | Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins |
| SG11201806639VA (en) * | 2016-02-04 | 2018-09-27 | Genovis Ab | New streptococcal proteases |
| TWI727883B (zh) * | 2016-08-24 | 2021-05-11 | 醣基生醫股份有限公司 | 利用醣苷內切酶突變體重塑醣蛋白及其使用方法 |
| FI3630968T3 (fi) | 2017-05-26 | 2024-07-24 | Genovis Ab | Entsyymejä glykaanien analysointiin |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CN112672764A (zh) | 2018-06-19 | 2021-04-16 | 格莱科斯生物医药公司 | 结合物 |
| CN112672765A (zh) | 2018-06-29 | 2021-04-16 | 格莱科斯生物医药公司 | 结合物 |
| US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
| CN111044731B (zh) * | 2019-12-19 | 2021-05-07 | 北京科技大学 | 脉冲温育免疫反应分离富集多肽药物中肽类杂质的方法 |
| WO2021142199A1 (en) | 2020-01-09 | 2021-07-15 | Mersana Therapeutics, Inc. | Site specific antibody-drug conjugates with peptide-containing linkers |
| GB202002072D0 (en) * | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| JP2023541698A (ja) * | 2020-09-21 | 2023-10-03 | 上海宝済薬業有限公司 | 組合せ医薬及びその使用 |
| TW202241954A (zh) | 2021-01-04 | 2022-11-01 | 美商梅爾莎納醫療公司 | 靶向ｂ７－ｈ４之抗體－藥物共軛體和使用彼之方法 |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| CN115873833B (zh) * | 2022-11-08 | 2024-08-16 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN117165643B (zh) * | 2023-08-17 | 2025-10-28 | 山东大学 | 一种糖苷内切酶在水解高甘露糖型n-糖蛋白中的应用 |
| WO2025098484A1 (zh) * | 2023-11-10 | 2025-05-15 | 上海齐鲁制药研究中心有限公司 | 新型Endo S2突变体酶 |
| WO2025180451A1 (zh) * | 2024-03-01 | 2025-09-04 | 上海齐鲁制药研究中心有限公司 | 新型Endo S2突变体酶 |
| WO2025248500A1 (en) | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Antibody drug conjugates that target enpp3 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| CN101889082A (zh) * | 2007-09-14 | 2010-11-17 | 季诺维斯公司 | 用于解离Fcgamma-受体-IgG复合物以及纯化与检测IgG的方法和试剂盒 |
| GB0821100D0 (en) | 2008-11-18 | 2008-12-24 | Hansa Medical Ab | Antibodies |
| ES2528321T3 (es) * | 2009-10-02 | 2015-02-06 | Roche Glycart Ag | Detección de a-fucosilación en anticuerpos |
-
2011
- 2011-09-13 GB GB201115841A patent/GB201115841D0/en not_active Ceased
-
2012
- 2012-09-12 CA CA2848230A patent/CA2848230C/en active Active
- 2012-09-12 EP EP12756523.2A patent/EP2756077B1/en active Active
- 2012-09-12 DK DK12756523.2T patent/DK2756077T3/en active
- 2012-09-12 PT PT127565232T patent/PT2756077T/pt unknown
- 2012-09-12 JP JP2014530196A patent/JP6076349B2/ja active Active
- 2012-09-12 CN CN201280044106.0A patent/CN103946377B/zh active Active
- 2012-09-12 ES ES12756523.2T patent/ES2627334T3/es active Active
- 2012-09-12 GB GB1406321.8A patent/GB2509284A/en not_active Withdrawn
- 2012-09-12 KR KR1020147009205A patent/KR102001427B1/ko active Active
- 2012-09-12 PL PL12756523T patent/PL2756077T3/pl unknown
- 2012-09-12 IN IN2163CHN2014 patent/IN2014CN02163A/en unknown
- 2012-09-12 SG SG11201400505YA patent/SG11201400505YA/en unknown
- 2012-09-12 MX MX2014002906A patent/MX347727B/es active IP Right Grant
- 2012-09-12 WO PCT/EP2012/067841 patent/WO2013037824A1/en not_active Ceased
- 2012-09-12 BR BR112014005816-4A patent/BR112014005816A2/pt not_active IP Right Cessation
- 2012-09-12 EA EA201490447A patent/EA028490B8/ru not_active IP Right Cessation
- 2012-09-12 US US14/343,938 patent/US9493752B2/en active Active
- 2012-09-12 AU AU2012307461A patent/AU2012307461B2/en active Active
-
2014
- 2014-03-09 IL IL231410A patent/IL231410A0/en unknown
- 2014-03-12 ZA ZA2014/01840A patent/ZA201401840B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014002906A (es) | 2014-10-17 |
| IN2014CN02163A (cg-RX-API-DMAC7.html) | 2015-05-29 |
| EP2756077A1 (en) | 2014-07-23 |
| CN103946377A (zh) | 2014-07-23 |
| IL231410A0 (en) | 2014-04-30 |
| JP6076349B2 (ja) | 2017-02-08 |
| EA028490B1 (ru) | 2017-11-30 |
| CA2848230C (en) | 2020-03-24 |
| PT2756077T (pt) | 2017-06-21 |
| US9493752B2 (en) | 2016-11-15 |
| SG11201400505YA (en) | 2014-04-28 |
| GB201115841D0 (en) | 2011-10-26 |
| DK2756077T3 (en) | 2017-07-03 |
| JP2014531205A (ja) | 2014-11-27 |
| PL2756077T3 (pl) | 2017-09-29 |
| CN103946377B (zh) | 2016-10-05 |
| KR20140081813A (ko) | 2014-07-01 |
| AU2012307461B2 (en) | 2016-08-18 |
| MX347727B (es) | 2017-05-10 |
| WO2013037824A1 (en) | 2013-03-21 |
| AU2012307461A1 (en) | 2014-03-27 |
| GB201406321D0 (en) | 2014-05-21 |
| CA2848230A1 (en) | 2013-03-21 |
| EP2756077B1 (en) | 2017-03-29 |
| EA201490447A1 (ru) | 2014-09-30 |
| GB2509284A (en) | 2014-06-25 |
| BR112014005816A2 (pt) | 2020-12-29 |
| KR102001427B1 (ko) | 2019-07-18 |
| NZ622172A (en) | 2016-04-29 |
| EA028490B8 (ru) | 2018-01-31 |
| US20140302519A1 (en) | 2014-10-09 |
| ZA201401840B (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2627334T3 (es) | Endoglucosidasa de streptococcus pyogenes y métodos para usarla | |
| CN104870468B (zh) | 用于制备经蛋白水解处理的多肽的方法 | |
| Zhang et al. | Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2 | |
| Takakura et al. | Tamavidins–novel avidin‐like biotin‐binding proteins from the Tamogitake mushroom | |
| JP2023103233A (ja) | Ｏ－糖タンパク質のためのプロテアーゼ及び結合ポリペプチド | |
| Dahl et al. | Carica papaya glutamine cyclotransferase belongs to a novel plant enzyme subfamily: cloning and characterization of the recombinant enzyme | |
| KR102399639B1 (ko) | 신규 엔도-β-N-아세틸글루코사미니다아제 | |
| Strydom et al. | An Angiogenic Protein from Bovine Serum and Milk—Purification and Primary Structure of Angiogenin‐2 | |
| Takeshita et al. | Determination of the complete cDNA sequence, construction of expression systems, and elucidation of fibrinolytic activity for Tapes japonica lysozyme | |
| ES2637314T3 (es) | Nuevas alfa-galactosidasas | |
| Kwon et al. | Recombinant adenylate kinase 3 from liver fluke Clonorchis sinensis for histochemical analysis and serodiagnosis of clonorchiasis | |
| WO2006073133A1 (ja) | 新規タンナーゼ遺伝子およびそのタンパク質 | |
| Thammasirirak et al. | New variant of quail egg white lysozyme identified by peptide mapping | |
| CN109810184A (zh) | 人nf155抗原、人nf155抗体检测试剂盒及其制备方法与应用 | |
| ES2297131T3 (es) | Produccion de ugppasa. | |
| Balestrieri et al. | Structural and functional insights into Aeropyrum pernix OppA, a member of a novel archaeal OppA subfamily | |
| JP2025538106A (ja) | ピーナッツに対する脱感作を誘導するための組成物及び方法 | |
| WO2002072624A2 (en) | Assays, methods and means for targeting streptococcal inhibitor of complement (sic) | |
| US20040106183A1 (en) | Shingolipid ceramide deacylase gene | |
| NZ622172B2 (en) | Endoglycosidase from streptococcus pyogenes and methods using it | |
| WANG et al. | Soluble Expression in Escherichia Coli and Purification of Human Carboxylesterase 1 | |
| US20060003330A1 (en) | Streptococcus pneumoniae pbp2x mini-protein and uses thereof | |
| CN1978456A (zh) | 人hNit3－ase基因序列、其编码蛋白及制备方法 |